36.28

0.90% -0.33

After Hours: 36.28

Veracyte Inc (VCYT)

Overview News Price History Option Chain Financials Discussions Forecast

Veracyte Inc stock is traded at $36.28, with a volume of 527.65K. It is down -0.90% in the last 24 hours and down -12.73% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Previous Close:

$36.61

Open:

$36.04

24h Volume:

527.65K

Relative Volume:

0.63

Market Cap:

$2.87B

Revenue:

$399.58M

Net Income/Loss:

$-54.04M

P/E Ratio:

-48.37

EPS:

-0.75

Net Cash Flow:

$40.13M

1W Performance:

+3.21%

1M Performance:

-12.73%

6M Performance:

+22.69%

1Y Performance:

-13.84%

1-Day Range:

$35.56

$36.46

1-Week Range:

$35.17

$37.22

52-Week Range:

$22.61

$50.71

Veracyte Inc Stock (VCYT) Company Profile

Name

Veracyte Inc

Sector

Healthcare (1110)

Industry

Diagnostics & Research (53)

Phone

(650) 243-6300

Address

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

824

Twitter

@veracyte

Next Earnings Date

2025-02-24

Latest SEC Filings

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCYT Veracyte Inc	36.28	2.89B	399.58M	-54.04M	40.13M	-0.75
TMO Thermo Fisher Scientific Inc	515.12	192.95B	44.56B	6.73B	6.29B	17.74
DHR Danaher Corp	211.25	147.43B	24.57B	3.60B	5.25B	5.0475
IDXX Idexx Laboratories Inc	630.73	50.70B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	126.34	35.90B	6.95B	1.30B	1.15B	4.5696
WAT Waters Corp	328.66	32.13B	3.17B	642.63M	539.81M	10.77

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Underweight
Oct-20-25	Initiated	Canaccord Genuity	Hold
Mar-20-25	Initiated	Craig Hallum	Buy
Dec-05-24	Downgrade	Goldman	Buy → Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-16-24	Initiated	UBS	Buy
Oct-10-24	Initiated	Guggenheim	Buy
Feb-23-24	Reiterated	Needham	Buy
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Nov-18-21	Resumed	Goldman	Buy
Jun-15-21	Initiated	Raymond James	Outperform
Feb-18-21	Resumed	Needham	Buy
Jan-28-21	Initiated	Truist	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-09-20	Initiated	Morgan Stanley	Underweight
Jul-31-19	Initiated	Lake Street	Buy
Jul-02-19	Initiated	Needham	Buy
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Janney	Buy → Neutral
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-31-17	Resumed	BTIG Research	Buy
Nov-14-16	Resumed	Leerink Partners	Outperform
Dec-18-15	Initiated	Cantor Fitzgerald	Buy
Jun-11-15	Reiterated	Leerink Partners	Outperform
Nov-26-13	Initiated	William Blair	Outperform

View All

Veracyte Inc Stock (VCYT) Latest News

Feb 18, 2026

Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - Finviz

Feb 18, 2026

Illinois Municipal Retirement Fund Takes Position in Veracyte, Inc. $VCYT - MarketBeat

Feb 18, 2026

Feb 17, 2026

Assessing Veracyte (VCYT) Valuation After Recent Share Price Volatility - Yahoo Finance

Feb 17, 2026

Feb 16, 2026

What Veracyte (VCYT)'s UBS Rating Reaffirmation and 2026 Outlook Means For Shareholders - Yahoo Finance

Feb 16, 2026

Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings - Bitget

Feb 16, 2026

NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro - Finviz

Feb 16, 2026

Public Sector Pension Investment Board Invests $10.54 Million in Veracyte, Inc. $VCYT - MarketBeat

Feb 16, 2026

UBS reaffirmed buy rating on Veracyte (VCYT) after strong Q4 testing revenue - MSN

Feb 16, 2026

Feb 15, 2026

UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue - Insider Monkey

Feb 15, 2026

Why Veracyte Inc. (12V) stock signals breakout potential2025 Winners & Losers & Free Reliable Trade Execution Plans - mfd.ru

Feb 15, 2026

Feb 14, 2026

13 Best Innovative Stocks to Buy According to Wall Street Analysts - Insider Monkey

Feb 14, 2026

Is Veracyte Inc. stock gaining market shareGold Moves & Expert Curated Trade Setups - mfd.ru

Feb 14, 2026

Feb 13, 2026

Pharma News: What is the next catalyst for Veracyte IncJuly 2025 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn

Feb 13, 2026

Veracyte (NASDAQ:VCYT) Rating Increased to Strong-Buy at Zacks Research - MarketBeat

Feb 13, 2026

Feb 12, 2026

Is Veracyte Inc. exposed to currency risks2025 Valuation Update & Daily Profit Maximizing Trade Tips - mfd.ru

Feb 12, 2026

56,756 Shares in Veracyte, Inc. $VCYT Bought by Thrivent Financial for Lutherans - MarketBeat

Feb 12, 2026

Feb 11, 2026

Is Veracyte Inc.’s ROIC above industry averageTrade Volume Report & Free Community Consensus Stock Picks - mfd.ru

Feb 11, 2026

Can Veracyte Inc. expand into new marketsJuly 2025 Selloffs & Real-Time Buy Signal Notifications - mfd.ru

Feb 11, 2026

Why Veracyte Inc. stock is considered a top pickJuly 2025 Final Week & Reliable Entry Point Trade Alerts - mfd.ru

Feb 11, 2026